ACOD1 and neoplasm: The combination of anti–PD-1 and Irg1 deficiency showed the most effective tumor inhibition and prolonged survival, with the mean life span being extended from 22 and 23 days in Irg1−/− mice (without PD-1 blockade) or anti–PD-1–treated Irg1+/+ mice, respectively, to 31 days (Fig. 5, C and D).